Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|October 19, 2015
Optimizing the Specialty Drug Pathway from Manufacturers to Pharmacies
Author(s)Davy James, Managing Editor
Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.
Advertisement
Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
4
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
5